The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Perioperative chemoimmunotherapy with durvalumab (Durva) in combination with cisplatin/gemcitabine (Cis/Gem) for operable muscle-invasive urothelial carcinoma (MIUC): Preplanned interim analysis of a single-arm phase II trial (SAKK 06/17).
 
Richard Cathomas
Consulting or Advisory Role - Amgen; Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Ipsen (Inst); Janssen-Cilag; MSD Oncology; Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Ulf Petrausch
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Janssen
 
Stefanie Hayoz
No Relationships to Disclose
 
Martina Schneider
No Relationships to Disclose
 
Julian Andreas Schardt
Honoraria - BMSi; MSD; Novartis
Consulting or Advisory Role - BMSi; MSD; Novartis
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - BMSi
 
Roland Seiler
No Relationships to Disclose
 
Andreas Erdmann
No Relationships to Disclose
 
Sacha Rothschild
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Serono (Inst)
Expert Testimony - AstraZeneca; Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Roche Pharma AG
 
Stefanie Aeppli
No Relationships to Disclose
 
Nicolas Mach
Stock and Other Ownership Interests - MaxiVax
Consulting or Advisory Role - AstraZeneca; BMSi; Merck; MSD; Novartis; Roche
Research Funding - MaxiVax (Inst)
 
Raeto Strebel
Honoraria - Janssen-Cilag
 
Boris A. Hadaschik
Consulting or Advisory Role - Bayer; Janssen; Lightpoint medical
Research Funding - Janssen
Patents, Royalties, Other Intellectual Property - Uromed
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Janssen
 
Dominik R. Berthold
Consulting or Advisory Role - Astellas Pharma; Janssen; Roche
Travel, Accommodations, Expenses - Astellas Oncology; Janssen; Roche
 
Miklos Pless
Consulting or Advisory Role - Abbvie; AstraZeneca; BMSi; Boehringer Ingelheim; Eisai; Merck; MSD; Novartis; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche; Takeda; Vifor Pharma
 
Deborah Zihler
No Relationships to Disclose
 
Mathias Schmid
Honoraria - BMSi; Celgene; Takeda
Consulting or Advisory Role - Amgen; BMSi
Travel, Accommodations, Expenses - Celgene
 
Christine Biaggi Rudolf
No Relationships to Disclose
 
Martin Spahn
No Relationships to Disclose